Fund Overlap
See which holdings any two equity ETFs have in common, along with top differences in exposure.
For overlap across multiple ETFs use Portfolio Builder
15
Number of overlapping holdings
17.9%
% of WDNA's 90 holdings also in CANC
31.3%
% of CANC's 48 holdings also in WDNA
Overlap by Weight
Sector Drift (WDNA minus CANC)
Overlapping Holdings
Top 5 only shown here. Please log-in or sign up for a Basic (Free) membership to view the complete list.
| Company | Weight in WDNA | Weight in CANC | Overlap | |
|---|---|---|---|---|
 |
ELI LILLY & CO | 2.7% | 5.3% | 2.7% |
|
BLUEPRINT MEDICINES CORP. | 2.6% | 2.9% | 2.6% |
|
BRIDGEBIO PHARMA, INC. | 2.4% | 4.1% | 2.4% |
|
GILEAD SCIENCES INC | 1.9% | 1.9% | 1.9% |
|
AMGEN INC | 1.7% | 2.9% | 1.7% |
Position Highlights (Non-Overlapping Exposures)
WDNA Overweight Relative to CANC
|
NATERA INC | 3.7% |
|
TWIST BIOSCIENCE CORP. | 3.3% |
 |
NOVOZYMES A/S-B SHARES | 2.9% |
|
VERICEL CORPORATION | 2.6% |
|
VERACYTE INC | 2.1% |
|
AGIOS PHARMACEUTICALS INC | 1.9% |
|
VERTEX PHARMACEUTICALS INC | 1.8% |
|
UNITED THERAPEUTICS CORP | 1.7% |
|
ALNYLAM PHARMACEUTICALS INC | 1.6% |
|
LABCORP HOLDINGS | 1.5% |
WDNA Underweight Relative to CANC
 |
ROCHE HOLDINGS LTD-SPONS ADR | -5.2% |
|
REVOLUTION MEDICINES, INC. | -4.8% |
 |
ASTRAZENECA PLC | -4.3% |
|
EXELIXIS INC | -4.0% |
|
NUVALENT, INC. CLASS A | -3.8% |
 |
ZAI LAB LTD. UNSPONSORED ADR | -3.7% |
 |
MERUS N.V. | -3.1% |
|
SUMMIT THERAPEUTICS INC | -3.1% |
 |
DAIICHI SANKYO CO LTD | -3.0% |
|
BRISTOL-MYERS SQUIBB CO | -3.0% |